
Photo: Twitter
').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Topics
Piramal | Piramal Enterprises | Stock Market

Photo: Twitter
').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Shares of Piramal Pharma closed at Rs 192 on Wednesday during their listing debut.
The company, which got listed separately following its demerger from Piramal Enterprises, was valued at Rs 22,882 crore at last close.
In FY22, the contract development and manufacturing (CDMO) vertical accounted for 59 per cent of its sales, complex hospital generics (CHG), 30 per cent and India consumer products business, 11 per cent.
Domestic brokerage Motilal Oswal has set a price target of Rs 210 for the stock.
“Using sum of the parts (SOTP), we value the CDMO business, CHG, and the ICH business based on 16x, 12x, and 18x FY24E EV/EBITDA respectively. We value Allergan JV (49 per cent stake) based on 18x FY24E PE,” it says.
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
First Published: Wed, October 19 2022. 18:09 IST
ClearBank has spent much of the past decade building the technology and regulatory infrastructure needed to challenge so... Read more
ClearBank’s progress shows that modern clearing and banking infrastructure can become a sizeable and profitable busine... Read more
There is something quietly symbolic about JPMorgan Chase choosing Berlin as its gateway into continental Europe. In a fo... Read more
There is a moment in every bull run when the narrative starts to fray. Not with a crash, not with a scandal, but with so... Read more
Coutts steps into private marketsCoutts, the private bank best known for serving Britain’s wealthiest families and the... Read more
How Crypto Moved from the Wild West to the Mainstream Financial SystemA long-form analysis of Bitcoin's journey from fri... Read more